Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of rocatinlimab in adults with moderate-to-severe asthma
jRCT2051240043Phase 2Suspended
- Sponsor
- Amgen
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of rocatinlimab in asthma (4 arms), sponsored by Amgen. Primary endpoint: Annualized Rate of Composite Endpoint for Exacerbations (CompEx) Events During the Blinded Treatment Period. Started Sep 2024; status: suspended.
02
Drugs
rocatinlimab
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2051240043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240043.